Background: The coronavirus 2019 disease (COVID-19) illness pandemic is one of the highest challenges in modern history, with nearly four million deaths confirmed, generating with this a serious psychological impact on the loved ones of the deceased. So far, the evidence regarding the impact of the COVID-19 pandemic on the grievers is scarce, and urgent evidence needs to be developed, especially for developing countries, such as Mexico, where the deaths caused by the COVID-19 are high.Methods: A cross-sectional study was conducted through the Duelo (Grief) COVID platform, a self-applied online treatment. The response of 5,224 participants, which was fully completed, included measurements of anxiety, depression, sleep quality, activation, PTSD related factors (avoidance and activation), and drugs consumed. Independent sample t tests, Cohen´s d, Chi-Square and ANOVA tests were conducted along with multinomial logistic regression.Outcomes: The results indicated that 90·4% of the participants showed a clinical symptomatology of depression, anxiety, and sleep affectations, 513 individuals informed they consumed substances. Antidepressants and Anxiolytics were the most common drugs reported. The most affected participants were young unemployed women, that consumed medicines, had a recent suicide attempt in the last 3 months, and lost someone due to COVID-19, or for some other reason in less than one month prior (all pInterpretation: Due to these results, an urgently implementation of broad psychological treatments on the general population is suggested in order to reduce the impact on mental health.Clinical Trial Registration Details: Registered in Clinical trials (NCT04638842).Funding Information: This study was funded by the Autonomous University of Ciudad Juárez (UACJ).Declaration of Interests: We declare no competing interests.Ethics Approval Statement: The Research Ethics Committee of the Autonomous University of Ciudad Juárez, México, provided the approval for this study. Reference code: CEI-2020-2-226. Before proceeding to answer the questionnaires, the participants needed to read the informed consent that is also available on the register study in Clinical Trials (NCT04638842). In order to receive the intervention, the participants needed to read and accept the informed consent. Only adults aged 18 or older were allowed to register, and their data will be protected, such as their email. No sensible data was required by the participants such as their name, telephone, address, socioeconomic status or location. Any modification of the trial protocol will be communicated to the Research Ethics Committee of the Autonomous University of Ciudad Juárez and Clinical Trials.
Read full abstract